Header Logo

Connection

Marta Batus to Retrospective Studies

Back to Details
This is a "connection" page, showing publications Marta Batus has written about Retrospective Studies.
Marta Batus
Connection Strength
0.485
Retrospective Studies
  1. Pulmonary metastasectomy in bone and soft tissue sarcoma with metastasis to the lung. Interact Cardiovasc Thorac Surg. 2021 11 22; 33(6):879-884.
    View in: PubMed
    Score: 0.106
  2. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. Acta Oncol. 2022 Jan; 61(1):38-44.
    View in: PubMed
    Score: 0.106
  3. Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and survival in undifferentiated pleomorphic sarcoma (NLR, PLR, and overall survival in UPS). Surg Oncol. 2023 Aug; 49:101949.
    View in: PubMed
    Score: 0.029
  4. Does synovial sarcoma grade predict oncologic outcomes, and does a low-grade variant exist? J Surg Oncol. 2022 Jun; 125(8):1301-1311.
    View in: PubMed
    Score: 0.027
  5. PET-CT staging affects time to treatment in sarcoma. Surg Oncol. 2022 May; 41:101732.
    View in: PubMed
    Score: 0.027
  6. What is the clinical impact of staging and surveillance PET-CT scan findings in patients with bone and soft tissue sarcoma? J Surg Oncol. 2022 Apr; 125(5):901-906.
    View in: PubMed
    Score: 0.027
  7. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Am J Clin Oncol. 2019 01; 42(1):1-5.
    View in: PubMed
    Score: 0.022
  8. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
    View in: PubMed
    Score: 0.019
  9. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience. Pediatr Blood Cancer. 2017 04; 64(4).
    View in: PubMed
    Score: 0.019
  10. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
    View in: PubMed
    Score: 0.018
  11. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.017
  12. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
    View in: PubMed
    Score: 0.015
  13. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.014
  14. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
    View in: PubMed
    Score: 0.013
  15. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.013
  16. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.